FFA
DNTH icon

Farther Finance Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Farther Finance Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51K Buy
36
+2
+6% +$175 ﹤0.01% 4964
2026
Q1 		$2.88K Sell
34
-205
-86% -$11.9K ﹤0.01% 4754
2025
Q4 		$9.85K Sell
239
-251
-51% -$9.73K ﹤0.01% 3925
2025
Q3 		$19.3K Buy
+490
New +$12.5K ﹤0.01% 3063

Other funds holding DNTH

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
FHC
First Horizon Corporation Memphis, Tennessee $2.6B AUM 23.72% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return

Farther Finance Advisors's DNTH Position: Q2 2026 in Review

Farther Finance Advisors increased its Dianthus Therapeutics (DNTH) stake by 5.9% in Q2 2026, buying an estimated $175 and bringing the position to 36 shares worth $3.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4964.

Farther Finance Advisors first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. The position peaked at $19.3K in Q3 2025. 15 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Farther Finance Advisors held 36 shares of Dianthus Therapeutics worth $3.51K as of Q2 2026.
  • Farther Finance Advisors bought 2 Dianthus Therapeutics shares in Q2 2026, an estimated $175.
  • Dianthus Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4964 holding.
  • Farther Finance Advisors first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Farther Finance Advisors's Dianthus Therapeutics position peaked at $19.3K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.